New drug trial targets rare kidney disease at genetic root
Disease control
Completed
This early study tested a drug called ELX-02 in 3 people with Alport syndrome, a genetic kidney disease. The goal was to see if the drug is safe and if it can reduce protein in the urine, a sign of kidney damage. Participants received daily injections for 8 weeks and were followe…
Phase: PHASE2 • Sponsor: Eloxx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC